Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Diabetes Care: The Future of Continuous Glucose Monitoring in the Management of Diabetes : Episode 14
Long-Term Outcomes Assessment
Experts share specific examples of how continuous glucose monitoring (CGM) technology has impacted diabetes-related health care costs and quality performance metrics, and discuss the methods used to measure and track CGM's long-term impact on diabetes complications, associated costs, and quality outcomes.
EP: 1.CGM: Redefining Type 2 Diabetes Management
EP: 2.Key Benefits of CGM Technology
EP: 3.CGM's Impact on Clinical Inertia
EP: 4.CGM vs Traditional Monitoring
EP: 5.Understanding CGM Metrics
EP: 6.Health Care System Integration
EP: 7.CGM Coverage and Access
EP: 8.Implementation Barriers
EP: 9.Overcoming Access Challenges
EP: 10.Adoption Strategies
EP: 11.The Metro Nashville Public Schools Initiative
EP: 12.Health Care Quality Impact
EP: 13.Population Outcomes and Return on Value With CGMs
Now Viewing
EP: 14.Long-Term Outcomes Assessment
EP: 15.Closing Perspectives
Video content above is prompted by the following:
- Please share specific examples of how CGM technology has impacted diabetes-related healthcare costs and quality performance metrics.
- What methods do you use to measure and track CGM's long-term impact on diabetes complications, associated costs, and quality outcomes?
Related Videos
Related Content
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025Article
The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More
